A Critical Literature Review of the Direct, Adverse Effects of Neuroleptics* *Also Known As Antipsychotics

Total Page:16

File Type:pdf, Size:1020Kb

A Critical Literature Review of the Direct, Adverse Effects of Neuroleptics* *Also Known As Antipsychotics A Critical Literature Review of the Direct, Adverse Effects of Neuroleptics* *also known as antipsychotics Essential Information for Mental Health Consumers, Carers, Families, Supporters and Clinicians Dr Kate Dorozenko and Dr Robyn Martin School of Occupational Therapy and Social Work Curtin University May 2017 ACKNOWLEDGEMENTS We acknowledge and pay our respects to those who have lost their lives as a result of their experiences of mental distress, and the consumers who are impacted and at times, debilitated by the adverse effects of neuroleptic drugs. We acknowledge the experiences of families and other supporters who stand beside their loved ones while advocating for change. We would like to thank Lyn Mahboub for her expert input to this report. Lyn’s input as Lived Experience Consultant has ensured our work is of the highest standard and never loses the central focus on consumers and families. We appreciate your capacity to stretch and challenge us morally, ethically and intellectually. We acknowledge Deb Sobott, the National Mental Health Consumer and Carer Forum representative who has worked closely with us in developing the scope and design of the project. Your grace, generosity, intellect and humour remind us of why we are called to work in this area and in this way. Finally, we thank the National Mental Health Consumer and Carer Forum who have funded this research. We believe your willingness to commission research in an area that is politically sensitive demonstrates leadership. A Critical Literature Review of the Direct, Adverse Effects of Neuroleptics* *also known as antipsychotics Essential Information for Mental Health Consumers, Carers, Families, Supporters and Clinicians Dr Kate Dorozenko and Dr Robyn Martin School of Occupational Therapy and Social Work Curtin University May 2017 Contents Foreword 1 Executive Summary 3 Background 5 Glossary 7 The History of Neuroleptic Drugs 11 Summary and Discussion — History 12 What is the Efficacy of Neuroleptic Drugs? 13 Neuroleptics for Early Episode Psychosis 15 Summary and Discussion — Neuroleptics for Early Episode Psychosis 15 Neuroleptics for People Diagnosed with Schizophrenia and Psychosis 16 First Generation Neuroleptics 16 Summary and Discussion — Efficacy of First Generation Neuroleptics 16 Second Generation Neuroleptics 16 Clozapine 17 Summary and Discussion — Efficacy of Second Generation Neuroleptics 17 Comparing the Efficacy of First and Second-Generation Neuroleptics 18 Summary and Discussion — Comparing the Efficacy of First and Second Generation Neuroleptics 18 The Long Term Use of Neuroleptics 19 Other Studies 20 Summary and Discussion – Long Term Use of Neuroleptic Drugs 20 Overall summary and discussion — Efficacy 20 Commonly Used Neuroleptic Drugs 21 Neuroleptic Prescribing 28 Summary and Discussion — Neuroleptic Prescribing 29 Neuroleptic Polypharmacy 29 Summary and Discussion — Neuroleptic Polypharmacy 30 Concurrent Prescribing of Neuroleptics and Other Drug Interactions 30 Summary and Discussion —Neuroleptic and Other Drug Interactions 31 The Direct Adverse Effects of Neuroleptics 32 Extrapyramidal Side Effects 32 Tardive Dyskinesia 33 Summary and Discussion — Extrapyramidal ‘Side’ Effects 34 Metabolic and Cardiovascular Adverse Effects 34 Summary and Discussion — Metabolic and Cardiovascular Adverse Effects 35 Hormonal Effects and Sexual Dysfunction 35 Summary and Discussion — Hormonal Effects and Sexual Dysfunction 36 Anticholinergic Effects 36 Summary and Discussion — Anticholinergic Effects 37 Cognitive Adverse Effects 37 Summary and Discussion — Cognitive Adverse Effects 38 Structural Brain Changes 38 Summary and Discussion — Structural Brain Changes 39 Neuroleptic Malignant Syndrome 39 Summary and Discussion — Neuroleptic Malignant Syndrome 39 Mortality 40 Summary and Discussion — Mortality 40 Overall Summary and Discussion — Adverse Effects of Neuroleptic Drugs 41 Withdrawal and Discontinuation 42 Clinical Views 42 Rapid Onset Psychosis 44 Consumer Views 45 Supporting Withdrawal and Discontinuation 46 Summary and Discussion — Withdrawal and Discontinuation 46 Alternative Responses 47 The Soteria Approach 47 Summary and Discussion — The Soteria Approach 48 The Open Dialogue Approach 48 Summary and Discussion — The Open Dialogue Approach 49 Hearing Voices Approach 50 Summary and Discussion — Hearing Voices Approach 51 Harm Reduction Approach 52 Summary and Discussion — Harm Reduction Approach 53 Shared Decision Making 53 Summary and Discussion — Shared Decision Making 54 Conclusion 55 References 57 Appendix 1: Methods 68 Foreword Whilst it has been a privilege to write this foreword, I deeply regret the circumstances by which I have come to do so. My name is Debra and I am the mother of a son permanently injured by neuroleptic (antipsychotic) drugs. I am also a mental health advocate and I have been conceivable chance of recovery, it is imperative that very fortunate to be associated with and benefit from you cultivate an awareness. This review will start you working alongside my colleagues at Curtin University on that journey to knowledge and awareness and I in Western Australia. I am also a proud member of the implore you to take advantage of the information within. National Mental Health Consumer and Carer Forum Had I been privy to the findings within this review (NMHCCF) who supported my initial research into the 20 years ago, our lives would have looked very different dangers associated with neuroleptics by providing today and as such I cannot overstate its importance for funding to commission this Critical Literature Review. consumers, families, carers and clinicians. On behalf of the NMHCCF, Curtin University researchers, So how did my son and I end up where we Dr Kate Dorozenko, Dr Robyn Martin in collaboration with subsist today? Wasn’t my son in the system getting consumer academic Ms Lyn Mahboub have produced ‘treatment’? Surely the system provided expert this compelling review which examines the direct and collaborative care and treatment? Well, actually — no. adverse effects of neuroleptic drugs. The treatment my son did get was standard and by that So why was it important to commission such I mean an ever changing concoction of neuroleptics a review? If I were to answer that question in just one (polypharmacy) year after year despite rapid and visible sentence I could look no further than psychiatrist, deterioration in both his mental and physical state. Niall (Jock) McLaren’s statement; “In plain language, I was a bystander to his fate with the profession of if you have mental problems these days, you live in psychiatry having purposeful dominion over our lives. dangerous times”. The mortality rate of those diagnosed I anguished over my son’s pleas for help. I cried when with schizophrenia is significantly higher in people he begged me to not let them inject him. I was incensed prescribed neuroleptics, dying on average 19 years when they dismissed my requests for cognitive younger than the general population. The evidence behavioural therapy and ultimately, my heart broke provided in this review substantiates the fact that there when I witnessed his metamorphosis from a handsome are significant physical and psychological impacts young man full of hope to what he became. Whilst he associated with neuroleptic drugs. And yet, despite this remains my beautiful boy, today you will see him as crucial evidence, neuroleptics continue to be routinely an overweight, scarred old man who suffers the agony of prescribed and people continue to be subjected to the tardive dyskinesia, the torment of akathisia, with multiple debilitating direct adverse effects and potential mortality. suicide attempts and no longer being able to utter one coherent sentence. Nothing can render a mother more If I was asked to write this foreword even 10 years ago, wretched than watching her child’s life dissolve before as a family member, I would have complied with the her eyes whilst being completely and utterly powerless unwritten rules if I wanted to be taken seriously, I must to do anything. be graceful; I must not be combative; I must not show emotion and above all, I must not give voice to my It has been argued that the direct and adverse effects personal experience. I no longer occupy that innocent, associated with neuroleptics would result in most unsullied space and the world my son and I now inhabit drugs in general medicine being removed from is tragic and cruel. I don’t seek company in this world the market. I find this remarkable, particularly so given — I want you or the person you care for to pursue an this review not only provides us with a list of the most informed pathway to a vastly different world and in commonly prescribed neuroleptics in Australia but order to find that alternative route and have the best more importantly, exposes the dire adverse and direct effects associated with each of those neuroleptic drugs. Foreword 1 We have to ask ourselves, how is it neuroleptics continue And in conclusion, I would like to leave you with to be the mainstay treatment given the dire mental an excerpt from Professor Peter Gøtzsche’s and physical outcomes? Our unwillingness to embrace ‘Psychiatry Gone Astray’: alternative safe treatments in the past has created this calamitous and dire situation which has, in turn, I am not against using drugs, provided we know given birth to an industry that exists entirely to ‘fix’ what we are doing and only use them in situations the problems that we, ourselves, have created. where they do more good than harm. Importantly, the review states “it became evident quickly Psychiatric drugs can be useful sometimes for that the literature was dominated by the voices and some patients, especially in short-term treatment, priorities of the clinical researchers and practitioners.” in acute situations. But my studies in this area lead If the views of the professions are the ‘only’ views me to a very uncomfortable conclusion: Our citizens afforded weight in treatment decisions with the would be far better off if we removed all the perspective of those whose lives who are critically psychotropic drugs from the market, as doctors impacted being ignored, how is it possible to arrive are unable to handle them.
Recommended publications
  • Pursuing Wellness Through Recovery and Integration
    FOR THE PROGRAM IPS 2012 Pursuing Wellness Through Recovery and Integration American Psychiatric Association 64TH INSTITUTE ON PSYCHIATRIC SERVICES NEW YORK CITY, OCTOBER 4–7 © JP Laffont/Sygma/Corbis 64th Institute on Psychiatric Services APA’s Leading Educational Conference on Public, Community, and Clinical Psychiatry Table OF Contents Table of Contents ������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 1 Scientific Program Committee and APA Officers and Staff �����������������������������������������������������������������������������������������������2–3 Key Locations at the Sheraton New York Hotel & Towers ����������������������������������������������������������������������������������������������������� 4 Educational Objectives �������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 4 Target Audiences �������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 4 Evaluation of the Institute on Psychiatric Services �������������������������������������������������������������������������������������������������������������������� 4 CME Certificate of Attendance Booth Hours �����������������������������������������������������������������������������������������������������������������������������
    [Show full text]
  • Psychiatric Medication Withdrawal
    JHPXXX10.1177/0022167818765331Journal of Humanistic PsychologyHall 765331research-article2018 Special Issue: Humanistic Perspectives on Understanding and Responding to Extreme States Journal of Humanistic Psychology 1 –10 Psychiatric Medication © The Author(s) 2018 Reprints and permissions: Withdrawal: Survivor sagepub.com/journalsPermissions.nav https://doi.org/10.1177/0022167818765331DOI: 10.1177/0022167818765331 Perspectives and journals.sagepub.com/home/jhp Clinical Practice Will Hall1 Abstract As patient/survivor movements continue to challenge reductionist biological views mental health and psychosis, there is rising skepticism toward psychiatric medications and growing interest in withdrawal and alternatives. This new perspective also calls for a rethinking of reductionist assumptions about psychiatric medications themselves. General medical patient experience with collaborative decision making for other conditions has broad implications for psychiatric drug withdrawal, and by recognizing psychiatric medications as psychoactive substances, addiction science also suggests a central role for social context and therapeutic common factors in medication withdrawal response. New understandings of madness and medications support an emerging reconsideration of what constitutes the very definition of “health,” where measuring the absence of disease symptoms gives way to a systems-based focus on self-management, social relationships, and adaptability. Keywords collaboration, DSM, mental disorder, psychiatric drugs, psychiatry, psychotherapy, qualitative research, schizophrenia, therapeutic relationship, psychosis 1Maastricht University MHeNS School for Mental Health and Neuroscience, Maastricht, Netherlands Corresponding Author: Will Hall, c/o 1017 Ashmount Avenue, Oakland, CA 94610, USA. Email: [email protected] 2 Journal of Humanistic Psychology 00(0) Emerging research urges greater caution in psychiatric medication treatment, including for psychotic disorders where medications have been considered indispensable (Murray et al., 2016).
    [Show full text]
  • Rethinking Psychiatric Care(2)
    Rethinking Psychiatric Care: If We Follow the Scientific Evidence, What Must We Do To Better Promote Long- term Recovery? The Common Wisdom The introduction of Thorazine into asylum medicine in 1955 “initiated a revolution in psychiatry, comparable to the introduction of penicillin in general medicine.” --Edward Shorter, A History of Psychiatry The Disabled Mentally Ill in the United States, 1955-2007 (under government care) Per 100,000 population 1500 1200 1315 900 600 543 300 213 0 1955 1987 2007 Source: Silverman, C. The Epidemiology of Depression (1968): 139. U.S. Social Security Administration Reports, 1987-2007. U.S. Disability in the Prozac Era Millions of adults, 18 to 66 years old 4 3 2 1 0 1987 1991 1995 1999 2003 2007 Source: U.S. Social Security Administration Reports, 1987-2007 Increased Treatment and Disability In U.S., 1990 to 2003 1990 2003 Number treated for psychiatric disorders 11.16 million 21.77 million Number on government disability 1.47 million 3.25 million due to mental illness Source: Surveys on prevalence of psychiatric disorders in 1990 and 2003, and percentage of those with disorders who were treated; SSI and SSDI disability data for 1990 to 2003. The Chemical Imbalance Theory of Mental Disorders • Arose from understanding of how drugs act on brain (1960s-1970s) • Investigations of dopamine theory of schizophrenia and serotonin theory of depression started in 1970s Findings re the Chemical Imbalance Theory of Mental Disorders A. Serotonin Theory of Depression • “Elevations or decrements in the functioning of serotonergic systems per se are not likely to be associated with depression.” --NIMH, 1984.
    [Show full text]
  • The Rise and Fall of the Diagnosis of Functional Psychoses: an Essay Per Bergsholm
    Bergsholm BMC Psychiatry (2016) 16:387 DOI 10.1186/s12888-016-1101-5 DEBATE Open Access Is schizophrenia disappearing? The rise and fall of the diagnosis of functional psychoses: an essay Per Bergsholm Abstract Background: The categories of functional psychoses build on views of influential professionals. There have long been four main categories – affective, schizophrenic, schizoaffective/cycloid/reactive/polymorphic, and delusional/ paranoid psychoses. The last three are included in “psychotic disorders”. However, this dichotomy and the distinctions between categories may have been over-estimated and contributed to lack of progress. Ten topics relevant for the diagnosis of functional psychoses: 1. The categories of functional psychoses have varied with time, place and professionals’ views, with moving boundaries, especially between schizophrenia and affective psychoses. 2. Catatonia is most often related to affective and organic psychoses, and paranoia is related to grandiosity and guilt, calling in question catatonic and paranoid schizophrenia. Arguments exist for schizophrenia being a “misdiagnosis”. 3. In some countries schizophrenia has been renamed, with positive consequences. 4. The doctrine of “unitary psychosis”, which included abnormal affect, was left in the second half of the 1800s. 5. This was followed by a dichotomy between schizophrenia and affective psychoses and broadening of the schizophrenia concept, whereas affective symptoms were strongly downgraded. 6. Many homogeneous psychoses with mixtures of schizophrenic and affective symptoms were described and related to “psychotic disorders”, although they might as well be affective disorders. 7. Critique of the extensive schizophrenia concept led to, in DSM-III and ICD-10, affective symptoms being exclusion criteria for schizophrenia and acceptance of mood-incongruent psychotic symptoms in affective psychoses.
    [Show full text]
  • GUIDELINES for the USE of PSYCHOTROPIC DRUGS a Clinical Handbook GUIDELINES for the USE of PSYCHOTROPIC DRUGS a Clinical Handbook
    GUIDELINES FOR THE USE OF PSYCHOTROPIC DRUGS A Clinical Handbook GUIDELINES FOR THE USE OF PSYCHOTROPIC DRUGS A Clinical Handbook Edited by HARVEY C STANCER, Ph.D., M.D., F.R.CP.(C) Clarke Institute of Psychiatry University of Toronto PAUL E. GARFINKEL, M.S., M.D., F.R.C.P.(C) Toronto General Hospital University of Toronto VIVIAN M. RAKOFF, M.A., M.B., F.R.CP.(C) Clarke Institute of Psychiatry University of Toronto LIMITED InternationalMT~il Medical Publishers Published in the UK and Europe by MTP Press Limited Falcon House Lancaster, England Published in the US by SPECTRUM PUBLICA nONS, INC. 175-20 Wexford Terrace Jamaica, NY 11432 Copyright © 1984 by Spectrum Publications, Inc. Softcover reprint of the hardcover 1st edition 1984 All rights reserved. No part of this book may be reproduced in any form, by photostat, microfilm, retrieval system, or any other means without prior written permission of the copyright holder or his licensee. ISBN 978-94-011-7620-0 ISBN 978-94-011-7618-7 (eBook) DOl 10.1007/978-94-011-7618-7 This volume is dedicated to Magda, Dorothy, and Gina Contributors William H. Anderson, M.D .• Assistant Clinical Professor of Psychiatry, Harvard Medical School; Acute Psychiatry Service, Massachusetts General Hospital, Boston, Massachusetts Jack D. Barchas, M.D .• Nancy Pritzker Laboratory of Behavioral Neurochemistry and Stanford Mental Health Clinical Research Center, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California Philip A. Berger, M.D .• Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California Janel S.
    [Show full text]
  • Antipsychotics-2020.Pdf
    © Mind 2020 Antipsychotics Explains what antipsychotics are used for, how the medication works, possible side effects and information about withdrawal. If you require this information in Word document format for compatibility with screen readers, please email: [email protected] Contents What are antipsychotics? ...................................................................................................................... 2 Could antipsychotics help me? .............................................................................................................. 5 How to take antipsychotics safely ......................................................................................................... 9 What dosage of antipsychotics should I be on? .................................................................................. 15 Antipsychotics during pregnancy and breastfeeding ........................................................................... 17 What side effects can antipsychotics cause? ....................................................................................... 20 What is a depot injection? ................................................................................................................... 30 How can I compare different antipsychotics? ..................................................................................... 31 Can I come off antipsychotics? ............................................................................................................ 41 Alternatives to antipsychotics
    [Show full text]
  • An Analysis of Psychologist Postdoctoral Psychopharmacology
    Antioch University AURA - Antioch University Repository and Archive Student & Alumni Scholarship, including Dissertations & Theses Dissertations & Theses 2016 An Analysis of Psychologist Postdoctoral Psychopharmacology Training Materials for Critiques of Neurobiological Hypotheses of Depression's Etiology, Critical Analyses of the DSM's Rigor, and for Consumer/Survivor/Ex- Patient Content. Chris William Nicholas Rowe Antioch University Seattle Follow this and additional works at: http://aura.antioch.edu/etds Part of the Educational Assessment, Evaluation, and Research Commons, Other Pharmacy and Pharmaceutical Sciences Commons, and the Psychology Commons Recommended Citation Rowe, Chris William Nicholas, "An Analysis of Psychologist Postdoctoral Psychopharmacology Training Materials for Critiques of Neurobiological Hypotheses of Depression's Etiology, Critical Analyses of the DSM's Rigor, and for Consumer/Survivor/Ex-Patient Content." (2016). Dissertations & Theses. 305. http://aura.antioch.edu/etds/305 This Dissertation is brought to you for free and open access by the Student & Alumni Scholarship, including Dissertations & Theses at AURA - Antioch University Repository and Archive. It has been accepted for inclusion in Dissertations & Theses by an authorized administrator of AURA - Antioch University Repository and Archive. For more information, please contact [email protected], [email protected]. AN ANALYSIS OF PSYCHOLOGIST POSTDOCTORAL PSYCHOPHARMACOLOGY TRAINING MATERIALS FOR CRITIQUES OF NEUROBIOLOGICAL HYPOTHESES OF DEPRESSION’S
    [Show full text]
  • Psychotic Symptoms
    Rethinking Psychiatry: ! History, Science, and the Long-term Effects of Psychiatric Medications Robert Whitaker May 2016 The Common Wisdom The introduction of chlorpromazine into asylum medicine in 1955 “initiated a revolution in psychiatry, comparable to the introduction of penicillin in general medicine.” ! --Edward Shorter, A History of Psychiatry The Disabled Mentally Ill in the United States (under government care) Per 100,000 population 1600 1559 1280 960 640 543 320 213 0 1955 1987 2010 Source: Silverman, C. The Epidemiology of Depression (1968): 139. U.S. Social Security Administration Reports, 1987-2007. U.S. Disability in the Prozac Era Millions of adults, 18 to 66 years old 5 4 3 2 1 0 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 Source: U.S. Social Security Administration Reports, 1987-2010 Disability Due to Psychiatric Disorders in New Zealand, 1991-2010 Adults 50000 40000 30000 20000 10000 0 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 Source: Statistics New Zealand, Annual reports, 1999-2010 Disability Due to Psychiatric Disorders in Australia, 1990-2011 Adults 250,000 200,000 150,000 100,000 50,000 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 Source: Australian Government, “Characteristics of Disability Support Pension Recipients, June 2011.” Sickness and and Disability Benefits for United Kingdom, 1998-2014 In thousands 1,200 1,080 960 About two-thirds of the claims were for a depressive or anxiety disorder. 840 720 600 1998 2000 2002 2004 2006 2008 2010 2012 2014 Source: S. Viola, J. Moncrieff. “Claims for sickness and disability benefits owing to mental disorders in the UK: trends from 1995 to 2014.” BJPsych Open 2 (2016):18-24 New Cases of Disability in Denmark Due to Mental Illness 9000 6750 4500 2250 0 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Source: Danish government, The Appeals Board, Statistics on Early Retirement.
    [Show full text]
  • Dangerous Gifts: Towards a New Wave of Mad Resistance
    Dangerous Gifts: Towards a New Wave of Mad Resistance Jonah Bossewitch Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2016 ©2016 Jonah Bossewitch All rights reserved ABSTRACT Dangerous Gifts: Towards a New Wave of Mad Resistance Jonah Bossewitch This dissertation examines significant shifts in the politics of psychiatric resistance and mental health activism that have appeared in the past decade. This new wave of resistance has emerged against the backdrop of an increasingly expansive diagnostic/treatment para- digm, and within the context of activist ideologies that can be traced through the veins of broader trends in social movements. In contrast to earlier generations of consumer/survivor/ex-patient activists, many of whom dogmatically challenged the existence of mental illness, the emerging wave of mad activists are demanding a voice in the production of psychiatric knowledge and greater control over the narration of their own identities. After years as a participant-observer at a leading radical mental health advocacy organization, The Icarus Project, I present an ethnography of conflicts at sites including Occupy Wall Street and the DSM-5 protests at the 2012 American Psychiatric Association conference. These studies bring this shift into focus, demonstrate how non-credentialed stakehold- ers continue to be silenced and marginalized, and help us understand the complex ideas these activists are expressing. This new wave of resistance emerged amidst a revolution in communication technologies, and throughout the dissertation I consider how activists are utilizing communications tools, and the ways in which their politics of resistance res- onate deeply with the communicative modalities and cultural practices across the web.
    [Show full text]
  • Maastricht Survey Progress Report January 2020
    SEPT. 11 2019 PROGRESS REPORT MAASTRICHT WORLD SURVEY ON ANTIPSYCHOTIC DRUG WITHDRAWAL WILL HALL, MAASTRICHT UNIVERSITY SCHOOL FOR MENTAL HEALTH AND NEUROSCIENCE [email protected] WORLD SURVEY ON ANTIPSYCHOTIC DRUG WITHDRAWAL INTRODUCTION ▸ Last year I (Will Hall) launched an online survey for the Maastricht World Study on Antipsychotic Medication Withdrawal. The study is for my PhD research at Maastricht University School for Mental Health and Neuroscience in the Netherlands, begun in 2016 and supervised by Dr. Jim van Os. ▸ Research on antipsychotic withdrawal brings together 15 years of experience working in the field, as well as my personal experiences as a schizophrenia diagnosis survivor, and reflects the collaboration of many user- survivor colleagues and allies over the years. ▸ I receive no funding for this research; my income is from my private practice as a therapist and as a training consultant. I also devote considerable time to community development work around mental health. So bear with me as the study proceeds at a more modest pace! WORLD SURVEY ON ANTIPSYCHOTIC DRUG WITHDRAWAL THANKS AND ACKNOWLEDGEMENTS ▸ This work has been an unpaid part of my PhD studies at Maastricht University. I have Translation Marian Goldstein greatly benefitted from the assistance and Radoslaw Stupak support of many collaborators since Joana Crawford Masami Glines inception, and I’m grateful for their Laura van Os contributions and guidance: Jade Bertaud Chiara Forzi Study Committee Feedback Recruitment Christian Rauschenberg Jim
    [Show full text]
  • Tardive Dyskinesia
    Task Force Reports This is the eighteenth in a series of reports approved by the Board of Trustees of the American Psychiatric Association to give wider dissemination to the findings of APA's many commissions, committees, and task forces that are called upon to evaluate the state of the art in a problem area of current concern to the profession, to related disciplines, and to the public. The findings, opinions, and conclusions of the report do not necessarily represent the views of the officers, trustees, or all members of the Association. Each report, however, does represent the thoughtful judgment and findings of the task force of experts who composed it. These reports are considered a substantive contribution to the ongoing analysis and evaluation of problems, programs, issues, and practices in a given area of concern. Alan A. Stone, M.D. President, APA, 1979-80 Library of Congress Catalogue No. 80-65372 Copyright 1980 by the American Psychiatric Association 1400 K Street, N.W., Washington, D.C. 20005 Printed in U.S.A. 2nd Printing October, 1983 TARDIVE DYSKINESIA Report of the American Psychiatric Association Task Force on Late Neurological Effects of Antipsychotic Drugs Ross J. Baldessarini, M.D., Chairperson Jonathan O. Cole, M.D. John M. Davis, M.D. George Gardos, M.D., Consultant Sheldon H. Preskorn, M.D., Falk Fellow George M. Simpson, M.D. Daniel Tarsy, M.D., Invited Neurologist Approved for Publication by the Council on Research and Development John M. Davis, M.D., Chairperson Charles Gaitz, M.D. Edward Joel Sachar, M.D. George Winokur, M.D.
    [Show full text]
  • Talking Point Papers to Encourage People to Consider Key Issues in Mental Health Research
    TALKING POINT PAPERS EDITION 1 JUNE 2018 Through the eyes of the observed: re-directing research on psychiatric drugs Authored by: Jasna Russo Biography Jasna Russo is an independent survivor researcher and consultant based in Berlin, Germany. She is a long-term activist in the international mental health service user/psychiatric survivor movement. Jasna has an MA in clinical psychology and is approaching completion of her PhD at Brunel University London. She has worked on both survivor-controlled and collaborative research projects, including several large-scale international studies. Her articles have been published in anthologies and journals in Germany and the UK. Together with Angela Sweeney, Jasna is the editor of Searching for a Rose Garden. Challenging Psychiatry, Fostering Mad Studies (PCCS Books, 2016). Contents 1. Introduction 4 2. Preliminary notes: on language, representativeness and the scope of this paper 6 3. About the structure of this paper 8 4. Psychiatric drugs: from a medical to a human rights issue 9 5. Experiential knowledge of psychiatric drugs 41 6. Inverting the research gaze: from assessing people to re-thinking treatment 20 A call to inquire and monitor prescriptions of psychiatric drugs 20 Exploring non-medical approaches to madness and distress 23 Merging research and practice 24 7. Summary 27 8. Acknowledgements 29 9. References 30 2 About the talking point series About the McPin Foundation The McPin Foundation are a mental health research charity. We are committed to improving the quality of mental health research so we need to know more about what works to improve the mental health of communities everywhere.
    [Show full text]